Inflammatory marker may highlight aggressive RCC treatment need medwireNews Molecular-targeted agents were approved in Japan in 2008, so 51.2% of the patients received such treatments following cytoreductive nephrectomy, whereas the others were given immunotherapy. Receipt of targeted agents doubled patients' chances for ... |
